RxDoctor Payments Data

Grant Defrancisco, DO

Psychiatry · Newnan, GANPI 1962909242

Payments from drug & device makers

$1,672in general payments, 2019–2025

Across 75 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$371
  • Teva Pharmaceuticals USA, Inc.$240
  • Otsuka America Pharmaceutical, Inc.$236
  • Alkermes, Inc.$151
  • E.r. Squibb & Sons, L.L.C.$137
  • Avanir Pharmaceuticals, Inc.$119
  • plus $417 from 8 others

What the payments were for

  • Food & beverage$1,56093%
  • Education$1117%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,672 in reported general payments places this provider in the 70th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$4,922
Medicare patients
21
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine23$110,635
IngrezzaValbenazine Tosylate12$102,467
Invega SustennaPaliperidone Palmitate20$62,273
BelsomraSuvorexant15$8,359
Lurasidone Hcl17$2,964
Aripiprazole64$2,101
Clozapine20$1,721
Oxcarbazepine35$1,260
Risperidone44$491
Gabapentin44$455
Divalproex Sodium21$412
Bupropion XlBupropion Hcl29$372
Quetiapine Fumarate34$362
Lamotrigine35$303
Hydroxyzine Pamoate17$287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$240$110,63523 claims
Neurocrine Biosciences, Inc.Ingrezza$67$102,46712 claims
Johnson & JohnsonInvega Sustenna$67$62,27320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Newnan

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →